University of California San Francisco
Give to UCSF
Patients of acute kidney injury might not need as much dialysis as patients with end-stage kidney disease, and might benefit more from weaning off dialysis to avoid risk for heart disease, infection, organ damage and death.
With fentanyl overdose deaths at an all-time high, a successful UCSF-funded pilot project to distribute fentanyl test strips is being expanded by California Gov. Gavin Newsome as part of his plan to address the crisis.
FDA approves palovarotene (Sohonos) for rare FOP, reducing HO by 54%. Significant step in improving lives of affected patients.
Zuranolone (Zurzuvae), the first pill for patients suffering from postpartum depression, is expected to be available by the end of 2023. Though it may relieve depressive symptoms, it has some drawbacks such as sedation and dangers in breastfeeding.
A clinical trial showed that MDMA, the so-called psychedelic drug also known as "ecstasy" or "molly," can be a powerful new tool in treating people with moderate-to-severe PTSD.
Three injectable medications, Wegovy, Ozempic and Mounjaro, are often taken as weight management drugs. UCSF health experts weigh in on the benefits and risks of taking the medications for obesity.
UCSF researchers are working across disease specialties. Diabetes researchers are looking at how oncologists use CAR T-cell therapy to reprogram a person’s immune system to attack cancer cells, for example. They hope to similarly reprogram the immune system to fight diabetes.
People looking to cut back on binge drinking alcohol can take a single pill of naltrexone right before drinking to curb consumption.
A new Alzheimer’s drug is expected to be approved by the Food and Drug Administration (FDA). However, the medication works best mostly for those in the earliest stages of Alzheimer’s.
A short course of antibiotics, Doxy-PEP, can prevent some STIs after condomless sex.
UCSF’s Nevan Krogan, PhD, is taking aim at the world’s deadliest diseases by uniting scientists and the biomedical industry to speed treatments.
Engineered immune cells. Supercharged scans. Drug implants. Gene manipulators. Blood biopsies. Read how these breakthroughs are transforming cancer care.
Two UCSF scientists – James Gardner, MD, PhD, and Rebeca de Pavia Fróes Rocha, PhD – have received Pew awards for their work in immunology as part of a program that supports promising early-career investigators.
UCSF researchers developed an approach to measure an over-the-counter allergy medication’s effectiveness in repairing brain damage from multiple sclerosis (MS), making it possible to also assess future therapies for the disorder.
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
UCSF researchers discover how gabapentin interacts with calcium channels, opening doors for more effective treatments in epilepsy and Lupus by influencing channel biogenesis.
UCSF faculty members Walter G. Gonzalez and Angela Phillips have been selected as Howard Hughes Medical Institute (HHMI) Freeman Hrabowski Scholars. With up to $8.6 million in support, they will conduct research, create inclusive lab environments, and make a significant impact on the future of science. Both scholars are committed to fostering diversity and promoting scientific breakthroughs.
A traditional African psychedelic plant medicine called ibogaine is the blueprint for two new drug candidates that could treat addiction and depression.
In a first, UCSF scientists created a molecular-level, 3D picture of how an odor molecule activates a human odorant receptor.
A sexual health strategy called Doxy-PEP, which involves taking doxycycline after condomless sex, is highly effective in reducing bacterial STIs but is still associated with a limited rise in resistant strains of bacteria.
Proof of an over-the-counter allergy drug’s ability to reverse progression of multiple sclerosis provides monumental change for MS patients.
Faranak Fattahi’s lab is a national leader in growing stem cells to model peripheral nerves, focusing on gastrointestinal diseases.
Emily Goldberg's lab studies what happens during aging to a particular set of immune cells: those embedded in fat tissue. She hypothesizes that changes to these cells during aging could be key to age-related inflammation.
Angela Phillips, PhD, leads research that could help predict future viruses like COVID and the antibodies we might use to treat them.
Balyn Zaro’s lab investigates the cause and consequence of genetic diversity in the immune system, in hopes that her discoveries can lead to better treatments for all patients.
Leanne Jones, PhD, is at the forefront of studying how stem cells are influenced by their surrounding environment and directed to differentiate into one type of cell or another – research that’s critical for stem cell therapies to be successful.
